Featured

Association of pre-existing autoimmune disease & irAEs secondary to ICI therapy



Published
Anna Claire Olsson-Brown, MBChB, The Clatterbridge Cancer Centre, Birkenhead, UK, discusses data from a large, real-world UK multicenter cohort on the association of pre-existing autoimmune disease (AID) and immune-related adverse events (irAEs) secondary to immune checkpoint inhibition therapy. Patients had received immune checkpoint inhibitors (ICIs) as standard of care (SOC) for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). The presence of pre-existing AIDs was correlated with clinically significant immune-related adverse events (iAEs). Overall, the study demonstrated pre-existing AIDs as a predisposing factor for the occurrence of iAEs. Interestingly, patients with pre-existing AIDs had superior overall survival (OS) versus those without, which had not previously been reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Category
Health
Be the first to comment